IBDEI14C ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,18148,1,3,0)
;;=3^DM Type 1 w/ Diab Foot Ulcer
;;^UTILITY(U,$J,358.3,18148,1,4,0)
;;=4^E10.621
;;^UTILITY(U,$J,358.3,18148,2)
;;=^5002616
;;^UTILITY(U,$J,358.3,18149,0)
;;=E10.622^^61^804^28
;;^UTILITY(U,$J,358.3,18149,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18149,1,3,0)
;;=3^DM Type 1 w/ Oth Skin Ulcer
;;^UTILITY(U,$J,358.3,18149,1,4,0)
;;=4^E10.622
;;^UTILITY(U,$J,358.3,18149,2)
;;=^5002617
;;^UTILITY(U,$J,358.3,18150,0)
;;=E10.51^^61^804^32
;;^UTILITY(U,$J,358.3,18150,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18150,1,3,0)
;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
;;^UTILITY(U,$J,358.3,18150,1,4,0)
;;=4^E10.51
;;^UTILITY(U,$J,358.3,18150,2)
;;=^5002610
;;^UTILITY(U,$J,358.3,18151,0)
;;=E10.52^^61^804^31
;;^UTILITY(U,$J,358.3,18151,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18151,1,3,0)
;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
;;^UTILITY(U,$J,358.3,18151,1,4,0)
;;=4^E10.52
;;^UTILITY(U,$J,358.3,18151,2)
;;=^5002611
;;^UTILITY(U,$J,358.3,18152,0)
;;=E11.00^^61^805^19
;;^UTILITY(U,$J,358.3,18152,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18152,1,3,0)
;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
;;^UTILITY(U,$J,358.3,18152,1,4,0)
;;=4^E11.00
;;^UTILITY(U,$J,358.3,18152,2)
;;=^5002627
;;^UTILITY(U,$J,358.3,18153,0)
;;=E11.01^^61^805^18
;;^UTILITY(U,$J,358.3,18153,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18153,1,3,0)
;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
;;^UTILITY(U,$J,358.3,18153,1,4,0)
;;=4^E11.01
;;^UTILITY(U,$J,358.3,18153,2)
;;=^5002628
;;^UTILITY(U,$J,358.3,18154,0)
;;=E11.21^^61^805^7
;;^UTILITY(U,$J,358.3,18154,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18154,1,3,0)
;;=3^DM Type 2 w/ Diab Nephropathy
;;^UTILITY(U,$J,358.3,18154,1,4,0)
;;=4^E11.21
;;^UTILITY(U,$J,358.3,18154,2)
;;=^5002629
;;^UTILITY(U,$J,358.3,18155,0)
;;=E11.22^^61^805^3
;;^UTILITY(U,$J,358.3,18155,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18155,1,3,0)
;;=3^DM Type 2 w/ Diab CKD
;;^UTILITY(U,$J,358.3,18155,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,18155,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,18156,0)
;;=E11.39^^61^805^28
;;^UTILITY(U,$J,358.3,18156,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18156,1,3,0)
;;=3^DM Type 2 w/ Oth Diab Ophth Compl
;;^UTILITY(U,$J,358.3,18156,1,4,0)
;;=4^E11.39
;;^UTILITY(U,$J,358.3,18156,2)
;;=^5002643
;;^UTILITY(U,$J,358.3,18157,0)
;;=E11.41^^61^805^6
;;^UTILITY(U,$J,358.3,18157,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18157,1,3,0)
;;=3^DM Type 2 w/ Diab Mononeuropathy
;;^UTILITY(U,$J,358.3,18157,1,4,0)
;;=4^E11.41
;;^UTILITY(U,$J,358.3,18157,2)
;;=^5002645
;;^UTILITY(U,$J,358.3,18158,0)
;;=E11.42^^61^805^13
;;^UTILITY(U,$J,358.3,18158,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18158,1,3,0)
;;=3^DM Type 2 w/ Diab Polyneuropathy
;;^UTILITY(U,$J,358.3,18158,1,4,0)
;;=4^E11.42
;;^UTILITY(U,$J,358.3,18158,2)
;;=^5002646
;;^UTILITY(U,$J,358.3,18159,0)
;;=E11.43^^61^805^2
;;^UTILITY(U,$J,358.3,18159,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18159,1,3,0)
;;=3^DM Type 2 w/ Diab Autonomic Polyneuropathy
;;^UTILITY(U,$J,358.3,18159,1,4,0)
;;=4^E11.43
;;^UTILITY(U,$J,358.3,18159,2)
;;=^5002647
;;^UTILITY(U,$J,358.3,18160,0)
;;=E11.44^^61^805^1
;;^UTILITY(U,$J,358.3,18160,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18160,1,3,0)
;;=3^DM Type 2 w/ Diab Amyotrophy
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI14C 3766 printed Apr 09, 2024@21:18:08 Page 2
IBDEI14C ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,18148,1,3,0)
+2 ;;=3^DM Type 1 w/ Diab Foot Ulcer
+3 ;;^UTILITY(U,$J,358.3,18148,1,4,0)
+4 ;;=4^E10.621
+5 ;;^UTILITY(U,$J,358.3,18148,2)
+6 ;;=^5002616
+7 ;;^UTILITY(U,$J,358.3,18149,0)
+8 ;;=E10.622^^61^804^28
+9 ;;^UTILITY(U,$J,358.3,18149,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,18149,1,3,0)
+12 ;;=3^DM Type 1 w/ Oth Skin Ulcer
+13 ;;^UTILITY(U,$J,358.3,18149,1,4,0)
+14 ;;=4^E10.622
+15 ;;^UTILITY(U,$J,358.3,18149,2)
+16 ;;=^5002617
+17 ;;^UTILITY(U,$J,358.3,18150,0)
+18 ;;=E10.51^^61^804^32
+19 ;;^UTILITY(U,$J,358.3,18150,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,18150,1,3,0)
+22 ;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
+23 ;;^UTILITY(U,$J,358.3,18150,1,4,0)
+24 ;;=4^E10.51
+25 ;;^UTILITY(U,$J,358.3,18150,2)
+26 ;;=^5002610
+27 ;;^UTILITY(U,$J,358.3,18151,0)
+28 ;;=E10.52^^61^804^31
+29 ;;^UTILITY(U,$J,358.3,18151,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,18151,1,3,0)
+32 ;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
+33 ;;^UTILITY(U,$J,358.3,18151,1,4,0)
+34 ;;=4^E10.52
+35 ;;^UTILITY(U,$J,358.3,18151,2)
+36 ;;=^5002611
+37 ;;^UTILITY(U,$J,358.3,18152,0)
+38 ;;=E11.00^^61^805^19
+39 ;;^UTILITY(U,$J,358.3,18152,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,18152,1,3,0)
+42 ;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
+43 ;;^UTILITY(U,$J,358.3,18152,1,4,0)
+44 ;;=4^E11.00
+45 ;;^UTILITY(U,$J,358.3,18152,2)
+46 ;;=^5002627
+47 ;;^UTILITY(U,$J,358.3,18153,0)
+48 ;;=E11.01^^61^805^18
+49 ;;^UTILITY(U,$J,358.3,18153,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,18153,1,3,0)
+52 ;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
+53 ;;^UTILITY(U,$J,358.3,18153,1,4,0)
+54 ;;=4^E11.01
+55 ;;^UTILITY(U,$J,358.3,18153,2)
+56 ;;=^5002628
+57 ;;^UTILITY(U,$J,358.3,18154,0)
+58 ;;=E11.21^^61^805^7
+59 ;;^UTILITY(U,$J,358.3,18154,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,18154,1,3,0)
+62 ;;=3^DM Type 2 w/ Diab Nephropathy
+63 ;;^UTILITY(U,$J,358.3,18154,1,4,0)
+64 ;;=4^E11.21
+65 ;;^UTILITY(U,$J,358.3,18154,2)
+66 ;;=^5002629
+67 ;;^UTILITY(U,$J,358.3,18155,0)
+68 ;;=E11.22^^61^805^3
+69 ;;^UTILITY(U,$J,358.3,18155,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,18155,1,3,0)
+72 ;;=3^DM Type 2 w/ Diab CKD
+73 ;;^UTILITY(U,$J,358.3,18155,1,4,0)
+74 ;;=4^E11.22
+75 ;;^UTILITY(U,$J,358.3,18155,2)
+76 ;;=^5002630
+77 ;;^UTILITY(U,$J,358.3,18156,0)
+78 ;;=E11.39^^61^805^28
+79 ;;^UTILITY(U,$J,358.3,18156,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,18156,1,3,0)
+82 ;;=3^DM Type 2 w/ Oth Diab Ophth Compl
+83 ;;^UTILITY(U,$J,358.3,18156,1,4,0)
+84 ;;=4^E11.39
+85 ;;^UTILITY(U,$J,358.3,18156,2)
+86 ;;=^5002643
+87 ;;^UTILITY(U,$J,358.3,18157,0)
+88 ;;=E11.41^^61^805^6
+89 ;;^UTILITY(U,$J,358.3,18157,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,18157,1,3,0)
+92 ;;=3^DM Type 2 w/ Diab Mononeuropathy
+93 ;;^UTILITY(U,$J,358.3,18157,1,4,0)
+94 ;;=4^E11.41
+95 ;;^UTILITY(U,$J,358.3,18157,2)
+96 ;;=^5002645
+97 ;;^UTILITY(U,$J,358.3,18158,0)
+98 ;;=E11.42^^61^805^13
+99 ;;^UTILITY(U,$J,358.3,18158,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,18158,1,3,0)
+102 ;;=3^DM Type 2 w/ Diab Polyneuropathy
+103 ;;^UTILITY(U,$J,358.3,18158,1,4,0)
+104 ;;=4^E11.42
+105 ;;^UTILITY(U,$J,358.3,18158,2)
+106 ;;=^5002646
+107 ;;^UTILITY(U,$J,358.3,18159,0)
+108 ;;=E11.43^^61^805^2
+109 ;;^UTILITY(U,$J,358.3,18159,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,18159,1,3,0)
+112 ;;=3^DM Type 2 w/ Diab Autonomic Polyneuropathy
+113 ;;^UTILITY(U,$J,358.3,18159,1,4,0)
+114 ;;=4^E11.43
+115 ;;^UTILITY(U,$J,358.3,18159,2)
+116 ;;=^5002647
+117 ;;^UTILITY(U,$J,358.3,18160,0)
+118 ;;=E11.44^^61^805^1
+119 ;;^UTILITY(U,$J,358.3,18160,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,18160,1,3,0)
+122 ;;=3^DM Type 2 w/ Diab Amyotrophy
